S&C Advises Biohaven on $200 Million Registered Offering of Common Shares

"S&C advised biopharmaceutical company Biohaven on a completed registered offering of $200 million of common shares, including the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Goldman Sachs, Leerink Partners, TD Cowen and Cantor acted as bookrunning managers."

S&C represented Biohaven in a registered offering of common shares. The offering consisted of $200 million of common shares and was completed with the full exercise of the underwriters’ option to purchase additional common shares. J.P. Morgan, Goldman Sachs, Leerink Partners, TD Cowen and Cantor acted as the bookrunning managers for the offering. Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience and oncology. S&C represented client Biohaven with a team composed by: Bob Downes, John Karol, Somin Park and Taylor Scott. Davis Wang, John Jo and Eli Dubin advised on tax matters.

S&C Advises Biohaven on $200 Million Registered Offering of Common Shares

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads